COMMUNIQUÉS West-GlobeNewswire

Axe Compute Reports $12 Million in Executed Agreements Providing $835 Thousand in Estimated Monthly Income Entering Q2 2026
01/04/2026
$12M of Contract Value Across 20+ Enterprise Customers, Providing $835 Thousand in Estimated Monthly Income Starting Q2 2026 PITTSBURGH, April 01, 2026 (GLOBE NEWSWIRE) -- Axe Compute Inc. (NASDAQ: AGPU), the newly [...]
Trevi Therapeutics to Participate in Upcoming Events
01/04/2026
NEW HAVEN, Conn., April 01, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the [...]
Major Shareholder Announcement
01/04/2026
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; April 1, 2026 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Orbis [...]
Grant of share-based long-term incentive instruments to members of the Board of Management and key employees
01/04/2026
ALK (ALKB:DC / Nasdaq Copenhagen: ALK B): According to the company’s remuneration policy adopted at the company's Annual General Meeting on 16 March 2026 and in line with the company’s usual practice, the Board of [...]
NTG Nordic Transport Group (“NTG”) announces the appointment of Carsten Trolle as CEO of its Air & Ocean division
01/04/2026
NTG is pleased to announce the appointment of Carsten Trolle as CEO of its Air & Ocean division, effective immediately. Carsten brings extensive expertise to NTG, having successfully managed and scaled multinational [...]
AskBio Announces Completion of Enrollment in Phase 2 Clinical Trial of AB-1002 Investigational Gene Therapy for Heart Failure
01/04/2026
Durham, N.C., April 01, 2026 (GLOBE NEWSWIRE) -- Final participant randomized in the GenePHIT Phase 2 clinical trial assessing safety and efficacy of AB-1002 for adults with non-ischemic cardiomyopathy and New York [...]
ONWARD Medical Publishes Convocation of the 2026 Annual General Meeting of Shareholders and Proposed Resolutions
01/04/2026
EINDHOVEN, the Netherlands, April 01, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and [...]
FibroBiologics Announces Pricing of $3 Million Public Offering
01/04/2026
HOUSTON, March 31, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the [...]
Algernon Health Announces Proposed Name Change to “Grey Matters Health Inc.” and a 10:1 Share Consolidation
01/04/2026
VANCOUVER, British Columbia, March 31, 2026 (GLOBE NEWSWIRE) -- Algernon Health Inc. (the “ Company ” or “ Algernon ”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, announces that it [...]
SpartaMax Claims Evaluated: Powerful Sparta Max Gummies for Maximum Performance Support in Men
01/04/2026
A 2026 informational overview of how the SpartaMax male enhancement gummy positions its Tongkat Ali, Ashwagandha, Maca Root, and Horny Goat Weed ingredient profile, individual dosage disclosures, formulation approach, [...]
Your Next Dental Appointment May Save Your Life
01/04/2026
Alberta Oral Health Professionals Urge Patients to Know the Signs of Oral Cancer EDMONTON, Alberta, March 31, 2026 (GLOBE NEWSWIRE) -- When you sit down for a routine dental visit, your oral health professional is doing [...]
Nxera Pharma’s Partner Centessa Pharmaceuticals to be Acquired by Lilly
01/04/2026
Lilly to gain ownership of Centessa's OX2R agonist pipeline designed to improve outcomes across sleep-wake disorders Centessa’s OX2R agonist pipeline was jointly discovered by Nxera and Centessa, and Nxera retains a [...]
20/20 BioLabs Reports Full Year 2025 Financial Results and Recent Operational Progress
31/03/2026
Full Year 2025 Revenue of $2.0 Million, up 17% from 2024 Gross Profit Increased 68% in FY 2025 and Gross Margin Expanded 900 bps State-Funded Firefighter Cancer Screening Program Expected to Drive Significant Revenue [...]
Axe Compute Inc. Reports Full-Year 2025 Financial Results
31/03/2026
Completed Strategic Transformation to AI Compute Infrastructure Raised $343.5 Million in Capital to Fund Digital Asset Treasury Strategy Solidified new leadership composition with world class CEO and board members [...]
Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 2025 Results and Corporate Highlights
31/03/2026
Shareholders approve acquisition of Aptose by Hanmi Pharmaceutical in “Go Private” transaction TUS+VEN+AZA triplet frontline therapy continues to demonstrate favorable safety and high rates of efficacy and MRD-negative [...]
NeuroSalt Claims Evaluated: What the Pink Salt Trick Research Says About Neuro Salt Supplementation for Nerve Health
31/03/2026
An informational overview of NeuroSalt ingredients, pink salt trick marketing claims, nerve pain supplement research context, pricing, refund policy, and what to know before buying Neuro Salt in 2026 Lakeland, FL, March [...]
ZyVersa Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update
31/03/2026
ZyVersa is advancing a highly differentiated pipeline focusing on inflammatory and renal diseases with a total accessible market >$100 billion. Inflammasome ASC Inhibitor IC 100 is a next generation drug designed for [...]
Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia
31/03/2026
Roluperidone has been de-risked by consistent positive results in two prior pivotal trials and remains the only late-stage drug candidate for this high-need population Efficacy topline data expected 2H 2027 BURLINGTON, [...]
HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results
31/03/2026
MIRAMAR, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to [...]

Pages